| Balance Sheets | 2025-09-27 | 2025-06-28 | 2025-03-29 | 2024-09-28 |
|---|---|---|---|---|
| Cash and cash equivalents | 207,097 | 182,824 | 229,356 | 210,171 |
| Trade receivables and contract assets, net of allowances for credit losses of 13,805 and 18,301, respectively | 734,482 | 767,569 | 756,629 | 754,207 |
| Inventories | 302,550 | 279,550 | 290,156 | 336,200 |
| Prepaid assets | 121,535 | 109,998 | 129,987 | 92,631 |
| Other current assets | 166,440 | 129,921 | 100,230 | 101,514 |
| Total current assets | 1,532,104 | 1,469,862 | 1,506,358 | 1,494,723 |
| Property, plant and equipment, net | 1,591,625 | 1,606,733 | 1,587,069 | 1,639,978 |
| Venture capital and strategic equity investments | 194,635 | 216,073 | 214,026 | 235,987 |
| Operating lease right-of-use assets, net | 374,273 | 385,756 | 402,908 | 385,133 |
| Goodwill | 2,922,281 | 2,936,265 | 2,873,402 | 3,124,592 |
| Intangible assets, net | 571,094 | 602,452 | 655,705 | 778,461 |
| Deferred tax assets | 36,907 | 46,943 | 48,794 | 37,963 |
| Other assets | 290,893 | 296,461 | 294,104 | 307,005 |
| Total assets | 7,513,812 | 7,560,545 | 7,582,366 | 8,003,842 |
| Accounts payable | 169,615 | 145,798 | 149,334 | 135,963 |
| Accrued compensation | 269,697 | 227,509 | 197,325 | 211,077 |
| Deferred revenue | 237,728 | 268,340 | 250,462 | 251,968 |
| Accrued liabilities | 228,895 | 231,567 | 242,467 | 208,124 |
| Other current liabilities | 215,953 | 207,224 | 211,467 | 205,089 |
| Total current liabilities | 1,121,888 | 1,080,438 | 1,051,055 | 1,012,221 |
| Long-term debt, net and finance leases | 2,185,453 | 2,332,374 | 2,510,754 | 2,326,653 |
| Operating lease right-of-use liabilities | 443,185 | 453,664 | 475,111 | 432,836 |
| Deferred tax liabilities | 123,007 | 109,273 | 107,268 | 167,746 |
| Other long-term liabilities | 189,462 | 185,210 | 196,396 | 236,669 |
| Total liabilities | 4,062,995 | 4,160,959 | 4,340,584 | 4,176,125 |
| Redeemable noncontrolling interests | 40,492 | 39,956 | 41,663 | 40,590 |
| Common stock, 0.01 par value 120,000 shares authorized 51,351 shares issued and 49,215 shares outstanding as of september27, 2025, and 51,141 shares issued and outstanding as of december28, 2024 | 514 | 513 | 512 | 517 |
| Additional paid-in capital | 2,015,665 | 1,992,718 | 1,978,052 | 1,971,413 |
| Retained earnings | 1,944,317 | 1,889,895 | 1,837,569 | 2,122,835 |
| Treasury stock, at cost, 2,136 and zero shares, as of september27, 2025 and december28, 2024, respectively | 363,431 | 363,338 | 356,551 | 119,621 |
| Accumulated other comprehensive loss | -191,616 | -166,467 | -265,246 | -192,871 |
| Total charles river laboratories international, inc. equity | 3,405,449 | 3,353,321 | 3,194,336 | 3,782,273 |
| Nonredeemable noncontrolling interest | 4,876 | 6,309 | 5,783 | 4,854 |
| Total equity | 3,410,325 | 3,359,630 | 3,200,119 | 3,787,127 |
| Total liabilities, redeemable noncontrolling interests and equity | 7,513,812 | 7,560,545 | 7,582,366 | 8,003,842 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)